Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy
Authors:
- Zachary Z. ReinsteinZRZachary Z. Reinstein
- Yue ZhangYZYue Zhang
- Oscar E. OspinaOOOscar E. Ospina
- Matt D. NicholsMNMatt D. Nichols
- Victoria A. ChuVCVictoria A. Chu
- Alvaro de Mingo. PulidoAPAlvaro de Mingo. Pulido
- Karol PrietoKPKarol Prieto
- Jonathan V. NguyenJNJonathan V. Nguyen
- Rui YinRYRui Yin
- Carlos Moran SeguraCarlos Moran Segura
- Ahmed UsmanAUAhmed Usman
- Brittney SellBSBrittney Sell
- 26 July 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (9) , 1631-1652
Abstract
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a ∼50% response rate to immune checkpoint blockade (ICB) therapy. To identify predictive biomarkers, we integrated bulk and single-cell RNA sequencing (RNA-seq) with spatial transcriptomics from a cohort of 186 samples from 116 patients, including bulk RNA-seq from 14 matched pairs pre- and post-ICB. In nonresponders, tumors show evidence of increased tumor proliferation, neuronal stem cell markers, and IL1. Responders have increased type I/II interferons and preexisting tissue resident (Trm) CD8 or Vδ1 γδ T cells that functionally converge with overlapping antigen-specific transcriptional programs and clonal expansion of public T-cell receptors. Spatial transcriptomics demonstrated colocalization of T cells with B and dendritic cells, which supply chemokines and costimulation. Lastly, ICB significantly increased clonal expansion or recruitment of Trm and Vδ1 cells in tumors specifically in responders, underscoring their therapeutic importance. These data identify potential clinically actionable biomarkers and therapeutic targets for MCC. Significance: MCC serves as a model of ICB response. We utilized the largest-to-date, multimodal MCC dataset (n = 116 patients) to uncover unique tumor-intrinsic properties and immune circuits that predict response. We identified CD8 Trm and Vδ1 T cells as clinically actionable mediators of ICB response in major histocompatibility complex–high and –low MCCs, respectively.Keywords
All Related Versions
Funding Information
- Alpha Omega Alpha Honor Medical Society (2019 AOA Carolyn E Kuckein Fellowship)
- National Cancer Institute (P30-CA076292)
- National Cancer Institute (T32 CA009560)
- National Cancer Institute (F30CA278298)
- National Cancer Institute (DP2 OD024475-01)
- National Cancer Institute (R35 GM144083)
- Leukemia and Lymphoma Society (1377-21)
- V Foundation for Cancer Research (T2021-019)
- National Comprehensive Cancer Network (NCCN-YIA 2019)
- National Cancer Institute (T32CA233399)
This publication has 49 references indexed in Scilit:
- Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancerCancer Cell, 2023
- Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From DiagnosisJAMA Dermatology, 2022
- The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapyCytokine & Growth Factor Reviews, 2021
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCancer Cell, 2020
- Top 10 Challenges in Cancer ImmunotherapyImmunity, 2020
- A Hox Code Defines Spinocerebellar Neuron Subtype RegionalizationCell Reports, 2019
- Plasmacytoid Dendritic Cells: Development, Regulation, and FunctionImmunity, 2019
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaCell, 2018
- OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cellsInternational Journal of Cancer, 2011
- Directed Expression of Gata2, Mash1, and Foxa2 Synergize to Induce the Serotonergic Neuron Phenotype During In Vitro Differentiation of Embryonic Stem CellsStem Cells, 2011